# Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort

> **NCT04979780** · — · COMPLETED · sponsor: **Bayer** · enrollment: 3708 (actual)

## Conditions studied

- Treatment of Venous Thromboembolism in Cancer Patients
- Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** Low molecular weight heparin (LMWH)
- **DRUG:** Direct Oral Anticoagulants (DOAC)

## Key facts

- **NCT ID:** NCT04979780
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-20
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-03-31
- **Target enrollment:** 3708 (ACTUAL)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04979780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04979780, "Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04979780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*